MassHealth stops covering drugs used only for obesity or overweight

MassHealth, the Massachusetts Medicaid program, stopped covering anti-obesity medications when they are prescribed only for weight loss, effective July 3, 2026 ^[1]. The change, laid out in Pharmacy Facts #271 (dated March 12, 2026, corrected), follows anticipated changes to state regulations at 130 CMR 406.413(B) ^[1]. MassHealth reported that roughly 22,000 members rely on Medicaid to cover anti-obesity drugs for weight loss alone ^[2].

The drug list in the bulletin is broad. It includes Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), Xenical (orlistat), phentermine products (Lomaira, Adipex-P), benzphetamine, diethylpropion and phendimetrazine ^[1]. The notice also states that any drug used off-label for weight loss is not payable for MassHealth patients ^[1].

What is still covered

GLP-1 and GIP/GLP-1 medicines remain covered after July 2, 2026, for members with approved prior authorizations for other medically accepted indications. The bulletin lists three: a body mass index above 27 with established cardiovascular disease, to reduce the risk of major adverse cardiovascular events; metabolic dysfunction-associated steatohepatitis (MASH); and a BMI of 30 or higher with moderate to severe obstructive sleep apnea ^[1].

The paperwork resets for everyone. Prior authorizations submitted before February 17, 2026 were end-dated for July 2, 2026 regardless of the indication, and must be resubmitted for claims to pay on or after July 3 ^[1]. Authorizations filed between February 17 and July 2, 2026 were processed by indication: those approved for obesity or overweight with no documented comorbidities expire July 2 ^[1]. Requests for the heart, liver or sleep apnea indications can be approved for up to six months, but only if supporting documentation is attached, such as an apnea-hypopnea index score for sleep apnea or a fibrosis stage for MASH. Without that documentation certifying severity, those authorizations were also end-dated for July 2, 2026 ^[1].

For members with diabetes or prediabetes, approvable authorizations expired July 2, and MassHealth says continued coverage requires switching to an antidiabetic GLP-1 ^[1]. On that list, Ozempic (semaglutide injection), Trulicity (dulaglutide), Victoza (liraglutide) and Mounjaro (tirzepatide) are preferred; Bydureon BCise, exenatide and Rybelsus (oral semaglutide) are non-preferred ^[1]. Requests for members under 21 are reviewed for medical necessity under federal EPSDT rules ^[1].

MassHealth spokesperson Stacey Nee told the Boston Globe the cut is expected to save about $15 million and described it as "a targeted approach to control costs, bring us in line with other states, and protect access to care as much as possible," citing last year's federal Medicaid changes ^[2]. Until the change took effect, Massachusetts was one of just 13 state Medicaid programs covering GLP-1s for obesity, according to KFF ^[2].

Why it matters for patients

For affected members, the practical result is that a prescription written only for weight loss will no longer pay at the pharmacy counter. Doctors interviewed by the Globe described three paths: going without, switching to cheaper and less effective drugs, or paying cash — which they said is often out of reach for Medicaid enrollees, since GLP-1s still typically cost hundreds of dollars a month ^[2].

The indication on the prior authorization now determines coverage, and the documentation requirements are specific. A member who qualifies on cardiovascular, MASH or sleep apnea grounds still needs a new authorization with severity documentation attached ^[1]. Tufts endocrinologist Dr. Richard Siegel said patients who still qualify through comorbidities tend to be older, leaving many younger patients without coverage, and that some patients have discussed taking smaller doses or stretching injections — approaches he said will be less effective ^[2].

Roughly 1,700 Massachusetts young people were on GLP-1s solely for weight loss, according to the Globe ^[2]. MassHealth will still cover those drugs for members under 21 where medical necessity is shown, considered case by case, though pediatricians told the Globe they are unsure how strict the justification standard will be ^[1][2].

The state's move runs opposite to a federal change: Medicare began a pilot program on July 1, 2026 covering some GLP-1s for Part D beneficiaries ^[2].

What happens next

The bulletin describes the policy as tied to "anticipated forthcoming changes" to 130 CMR 406.413(B); the sources do not say when the final regulation will be published ^[1]. Approvals granted for MACE, MASH or OSA run up to six months, so a first round of renewals would come due by early 2027 ^[1]. Whether the estimated $15 million in savings materializes, and what happens to members who lose access, is not yet known from these sources.